Bolt Biotherapeutics (NASDAQ:BOLT) Releases Quarterly Earnings Results, Misses Estimates By $1.18 EPS

Bolt Biotherapeutics (NASDAQ:BOLT) announced its quarterly earnings results on Tuesday. The company reported ($4.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.39) by ($1.18), FiscalAI reports. Bolt Biotherapeutics had a negative return on equity of 100.89% and a negative net margin of 455.15%.The company had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.50 million.

Bolt Biotherapeutics Trading Down 0.3%

NASDAQ BOLT traded down $0.01 on Tuesday, hitting $3.98. The company’s stock had a trading volume of 10,182 shares, compared to its average volume of 24,902. The company has a quick ratio of 3.51, a current ratio of 3.51 and a debt-to-equity ratio of 0.98. Bolt Biotherapeutics has a 1-year low of $3.75 and a 1-year high of $7.20. The company’s 50-day moving average is $4.17 and its 200 day moving average is $4.65. The firm has a market cap of $7.65 million, a PE ratio of -0.24 and a beta of 1.18.

Hedge Funds Weigh In On Bolt Biotherapeutics

A number of hedge funds have recently modified their holdings of BOLT. Renaissance Technologies LLC increased its holdings in Bolt Biotherapeutics by 92.2% in the fourth quarter. Renaissance Technologies LLC now owns 55,025 shares of the company’s stock valued at $301,000 after purchasing an additional 26,400 shares during the period. Susquehanna International Group LLP acquired a new position in Bolt Biotherapeutics during the 3rd quarter worth about $89,000. Shay Capital LLC acquired a new position in Bolt Biotherapeutics during the 3rd quarter worth about $85,000. Finally, Squarepoint Ops LLC grew its position in shares of Bolt Biotherapeutics by 19.8% in the 3rd quarter. Squarepoint Ops LLC now owns 14,836 shares of the company’s stock valued at $79,000 after buying an additional 2,448 shares during the last quarter. Institutional investors and hedge funds own 86.70% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the company. Weiss Ratings restated a “sell (e+)” rating on shares of Bolt Biotherapeutics in a research report on Friday, July 17th. HC Wainwright reiterated a “buy” rating and issued a $7.00 target price on shares of Bolt Biotherapeutics in a research report on Thursday, May 28th. Finally, Rodman & Renshaw initiated coverage on Bolt Biotherapeutics in a research note on Thursday, May 28th. They set a “buy” rating and a $22.00 price target on the stock. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $34.67.

About Bolt Biotherapeutics

Bolt Biotherapeutics is a clinical-stage immuno-oncology company focused on developing novel targeted therapies that engage both innate and adaptive immune responses against cancer. The company’s proprietary Biologics-Driven Checkpoint (BDC) platform combines tumor-targeting antibodies with innate immune agonists to activate antigen-presenting cells within the tumor microenvironment, thereby promoting robust T-cell mediated tumor cell killing. Its lead candidate, BDC-1001, couples a HER2-directed monoclonal antibody with a Toll-like receptor 7/8 agonist and is currently in Phase I clinical trials for HER2-positive solid tumors.